(AOF) – Amgen today announced two appointments to its management team in the areas of research and development (R&D) and technology: James Bradner joins the group as executive vice president responsible for research and development and chief scientific officer, replacing David M. Reese, named executive vice president and chief technology officer. Both Bradner and Reese will report to Robert A. Bradway, CEO of Amgen.
James Bradner will be responsible for advancing Amgen’s pipeline, which includes drugs at all stages of development across the company’s four therapeutic areas: oncology, anti-inflammatories, general medicine and rare diseases, in addition to biosimilars.
Head of research at Amgen since 2018, David M. Reese will now be responsible for accelerating the use of technology and AI in all facets of the organization. He most recently served as the lead architect of Amgen’s artificial intelligence (AI) initiatives.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
